Prognostic value and therapeutic potential of TREM-1 in Streptococcus pyogenes- induced sepsis.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsHorst, Sarah A
MetadataShow full item record
AbstractTREM-1 (triggering receptor expressed on myeloid cells) is a surface molecule expressed on neutrophils and macrophages which has been implicated in the amplification of inflammatory responses triggered during infection. In the present study, we have investigated the clinical significance of TREM-1 in Streptococcus pyogenes-induced severe sepsis in both experimentally infected mice as well as in patients with streptococcal toxic shock. We found that S. pyogenes induced a dose-dependent upregulation of TREM-1 in in vitro cultured phagocytic cells and in the organs of S. pyogenes-infected mice. Furthermore, we reported a positive correlation between serum levels of soluble TREM-1 (sTREM-1) and disease severity in infected patients as well as in experimentally infected mice. Hence, sTREM-1 may represent a useful surrogate marker for streptococcal sepsis. We found that modulation of TREM-1 by administration of the TREM-1 decoy receptor rTREM-1/Fc substantially attenuated the synthesis of inflammatory cytokines. More importantly, treatment of S. pyogenes-infected septic mice with rTREM-1/Fc or the synthetically produced conserved extracellular domain LP17 significantly improved disease outcome. In summary, our data suggest that TREM-1 may not only represent a valuable marker for S. pyogenes infection severity but it may also be an attractive target for the treatment of streptococcal sepsis.
CitationPrognostic value and therapeutic potential of TREM-1 in Streptococcus pyogenes- induced sepsis. 2013, 5 (6):581-90 J Innate Immun
AffiliationDep. of infection immunology, Helmholtz Centre for infection research, Braunschweig, Germany
JournalJournal of innate immunity
The following license files are associated with this item:
- Azithromycin acts as an immunomodulatory agent to suppress the expression of TREM-1 in Bacillus pyocyaneus-induced sepsis.
- Authors: Tong J, Liu ZC, Wang DX
- Issue date: 2011 Aug 30
- Targeting TREM-1 Signaling in the Presence of Antibiotics is Effective Against Streptococcal Toxic-Shock-Like Syndrome (STSLS) Caused by Streptococcus suis.
- Authors: Yang C, Zhao J, Lin L, Pan S, Fu L, Han L, Jin M, Zhou R, Zhang A
- Issue date: 2015
- Early serum levels of soluble triggering receptor expressed on myeloid cells-1 in septic patients: correlation with monocyte gene expression.
- Authors: Dimopoulou I, Pelekanou A, Mavrou I, Savva A, Tzanela M, Kotsaki A, Kardara M, Orfanos SE, Kotanidou A, Giamarellos-Bourboulis EJ
- Issue date: 2012 Jun
- Differential pattern of cell-surface and soluble TREM-1 between sepsis and SIRS.
- Authors: Oku R, Oda S, Nakada TA, Sadahiro T, Nakamura M, Hirayama Y, Abe R, Tateishi Y, Ito M, Iseki T, Hirasawa H
- Issue date: 2013 Jan
- TREM-1 signaling promotes host defense during the early stage of infection with highly pathogenic Streptococcus suis.
- Authors: Yang C, Chen B, Zhao J, Lin L, Han L, Pan S, Fu L, Jin M, Chen H, Zhang A
- Issue date: 2015 Aug